{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:56Z","timestamp":1761897056376,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009240","name":"Sveriges Kommuner och Landsting","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100009240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s13300-019-0632-4","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T23:31:29Z","timestamp":1557876689000},"page":"1523-1530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2569-4160","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Eliasson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Ekelund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikard","family":"Amberntsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervete","family":"Miftaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Marie","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"issue":"7","key":"632_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"632_CR2","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"Melanie J. Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"22","key":"632_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"632_CR4","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s00125-016-3971-y","volume":"59","author":"A Norhammar","year":"2016","unstructured":"Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006\u20132013. Diabetologia. 2016;59(8):1692\u2013701.","journal-title":"Diabetologia"},{"key":"632_CR5","doi-asserted-by":"crossref","unstructured":"Eliasson B, Gudbjornsdottir S. Diabetes care\u2014improvement through measurement. Diabetes Res Clin Pract. 2014;106(Suppl 2):S291\u20134.","DOI":"10.1016\/S0168-8227(14)70732-6"},{"issue":"6","key":"632_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461\u201370.","journal-title":"Ann Intern Med"},{"issue":"9","key":"632_CR7","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"2","key":"632_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10166","key":"632_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"Thomas A Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"The Lancet"},{"issue":"7","key":"632_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"632_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Stephen D. Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"New England Journal of Medicine"},{"key":"632_CR12","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson AM, Franzen S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.","journal-title":"BMJ"},{"issue":"22","key":"632_CR13","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","volume":"71","author":"MA Cavender","year":"2018","unstructured":"Cavender MA, Norhammar A, Birkeland KI, Jorgensen ME, Wilding JP, Khunti K, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497\u2013506.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"632_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","volume":"54","author":"M Monami","year":"2017","unstructured":"Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(1):19\u201336.","journal-title":"Acta Diabetol"},{"issue":"25","key":"632_CR15","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","volume":"139","author":"Elisabetta Patorno","year":"2019","unstructured":"Patorno E, Pawar A, Franklin JM, Najafzadeh M, Deruaz-Luyet A, Brodovicz KG, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) study. Circulation. 2019. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039177.","journal-title":"Circulation"},{"issue":"14","key":"632_CR16","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","volume":"137","author":"JA Udell","year":"2018","unstructured":"Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation. 2018;137(14):1450\u20139.","journal-title":"Circulation"},{"issue":"2","key":"632_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/1753-0407.12616","volume":"10","author":"Z Bloomgarden","year":"2018","unstructured":"Bloomgarden Z. The kidney and cardiovascular outcome trials. J Diabetes. 2018;10(2):88\u20139.","journal-title":"J Diabetes"},{"key":"632_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13692","author":"RA Scholtes","year":"2019","unstructured":"Scholtes RA, van Baar MJB, Lytvyn Y, Bjornstad P, Nieuwdorp M, Cherney DZI, et al. Sodium glucose cotransporter (SGLT)-2 inhibitors: do we need them for glucose-lowering, for cardiorenal protection or both? Diabetes Obes Metab. 2019. https:\/\/doi.org\/10.1111\/dom.13692.","journal-title":"Diabetes Obes Metab"},{"key":"632_CR19","doi-asserted-by":"crossref","unstructured":"van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney\u2014from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017;12(4):700\u201310.","DOI":"10.2215\/CJN.06080616"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-0632-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-019-0632-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-019-0632-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:37:38Z","timestamp":1724413058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-019-0632-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1007\/s13300-019-0632-4","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}